203 related articles for article (PubMed ID: 21787417)
1. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib.
Harmon CS; DePrimo SE; Raymond E; Cheng AL; Boucher E; Douillard JY; Lim HY; Kim JS; Lechuga MJ; Lanzalone S; Lin X; Faivre S
J Transl Med; 2011 Jul; 9():120. PubMed ID: 21787417
[TBL] [Abstract][Full Text] [Related]
2. Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.
Keyvanjah K; DePrimo SE; Harmon CS; Huang X; Kern KA; Carley W
J Transl Med; 2012 Aug; 10():165. PubMed ID: 22897944
[TBL] [Abstract][Full Text] [Related]
3. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
5. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy.
Sahani DV; Jiang T; Hayano K; Duda DG; Catalano OA; Ancukiewicz M; Jain RK; Zhu AX
J Hematol Oncol; 2013 Jul; 6():51. PubMed ID: 23842041
[TBL] [Abstract][Full Text] [Related]
7. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.
Zhu AX; Duda DG; Ancukiewicz M; di Tomaso E; Clark JW; Miksad R; Fuchs CS; Ryan DP; Jain RK
Clin Cancer Res; 2011 Feb; 17(4):918-27. PubMed ID: 20843836
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
9. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours.
Zurita AJ; Khajavi M; Wu HK; Tye L; Huang X; Kulke MH; Lenz HJ; Meropol NJ; Carley W; DePrimo SE; Lin E; Wang X; Harmon CS; Heymach JV
Br J Cancer; 2015 Mar; 112(7):1199-205. PubMed ID: 25756398
[TBL] [Abstract][Full Text] [Related]
10. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
Deprimo SE; Huang X; Blackstein ME; Garrett CR; Harmon CS; Schöffski P; Shah MH; Verweij J; Baum CM; Demetri GD
Clin Cancer Res; 2009 Sep; 15(18):5869-77. PubMed ID: 19737953
[TBL] [Abstract][Full Text] [Related]
11. Early development of sunitinib in hepatocellular carcinoma.
Zhu AX; Raymond E
Expert Rev Anticancer Ther; 2009 Jan; 9(1):143-50. PubMed ID: 19105714
[TBL] [Abstract][Full Text] [Related]
12. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Zhu AX; Duda DG; Sahani DV; Jain RK
Cancer J; 2009; 15(4):263-8. PubMed ID: 19672141
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Zhu AX; Sahani DV; Duda DG; di Tomaso E; Ancukiewicz M; Catalano OA; Sindhwani V; Blaszkowsky LS; Yoon SS; Lahdenranta J; Bhargava P; Meyerhardt J; Clark JW; Kwak EL; Hezel AF; Miksad R; Abrams TA; Enzinger PC; Fuchs CS; Ryan DP; Jain RK
J Clin Oncol; 2009 Jun; 27(18):3027-35. PubMed ID: 19470923
[TBL] [Abstract][Full Text] [Related]
14. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.
Norden-Zfoni A; Desai J; Manola J; Beaudry P; Force J; Maki R; Folkman J; Bello C; Baum C; DePrimo SE; Shalinsky DR; Demetri GD; Heymach JV
Clin Cancer Res; 2007 May; 13(9):2643-50. PubMed ID: 17473195
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers.
Kontovinis LF; Papazisis KT; Touplikioti P; Andreadis C; Mouratidou D; Kortsaris AH
BMC Cancer; 2009 Mar; 9():82. PubMed ID: 19284623
[TBL] [Abstract][Full Text] [Related]
16. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors.
Strosberg JR; Weber JM; Choi J; Campos TL; Valone TL; Han G; Schell MJ; Kvols LK
Ann Oncol; 2012 Sep; 23(9):2335-2341. PubMed ID: 22317769
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.
Faivre S; Raymond E; Boucher E; Douillard J; Lim HY; Kim JS; Zappa M; Lanzalone S; Lin X; Deprimo S; Harmon C; Ruiz-Garcia A; Lechuga MJ; Cheng AL
Lancet Oncol; 2009 Aug; 10(8):794-800. PubMed ID: 19586800
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
Liu G; Jeraj R; Vanderhoek M; Perlman S; Kolesar J; Harrison M; Simoncic U; Eickhoff J; Carmichael L; Chao B; Marnocha R; Ivy P; Wilding G
Clin Cancer Res; 2011 Dec; 17(24):7634-44. PubMed ID: 22038997
[TBL] [Abstract][Full Text] [Related]
20. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
Zhu AX; Finn RS; Mulcahy M; Gurtler J; Sun W; Schwartz JD; Dalal RP; Joshi A; Hozak RR; Xu Y; Ancukiewicz M; Jain RK; Nugent FW; Duda DG; Stuart K
Clin Cancer Res; 2013 Dec; 19(23):6614-23. PubMed ID: 24088738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
